Identification and evaluation of antivirals for Rift Valley fever virus

Yuekun Lang, Yonghai Li, Dane Jasperson, Jamie Henningson, Jinhwa Lee, Jingjiao Ma, Yuhao Li, Michael Duff, Haixia Liu, Dingping Bai, Scott McVey, Juergen A. Richt, Tetsuro Ikegami, William C. Wilson, Wenjun Ma

Research output: Contribution to journalReview article

Abstract

Rift Valley fever virus (RVFV) is the causative agent of Rift Valley fever (RVF) that affects both livestock and humans. There are neither fully licensed RVF vaccines available for human or animal use, nor effective antiviral drugs approved for human use in the U.S. To identify antiviral compounds effective for RVF, we developed and employed a cell-based high-throughput assay using a recombinant RVFV MP-12 strain, which expresses Renilla luciferase in place of the NSs protein, to screen 727 small compounds purchased from the National Institutes of Health. Twenty-three compounds were initially identified using the screening assay. Two compounds, 6-azauridine and mitoxantrone, also inhibited the replication of the parental MP-12 strain encoding the NSs gene, with limited cytotoxic effects. The respective 50% inhibitory concentrations were 29.07 μM and 79.85 μM when tested with the parental MP-12 strain at a multiplicity of infection of 2. The compounds were further evaluated using the STAT-1 KO mouse model. At one hour post intranasal inoculation of MP-12 strain, mice were intranasally treated with each indicated compound twice daily. Mice treated with either placebo or 6-azauridine displayed severe weight loss and reached the threshold for euthanasia with obvious neurologic symptoms. Onset of disease was, however, delayed in mice treated with either ribavirin or mitoxantrone. The results indicated that mitoxantrone can reduce the severity of diseases in RVFV-infected mice. Our studies build the foundation for the initial screening and efficacy studies of RVF antivirals in a BSL-2 environment, avoiding the higher risks of BSL-3 exposure with wild-type virus.

Original languageEnglish (US)
Pages (from-to)110-116
Number of pages7
JournalVeterinary Microbiology
Volume230
DOIs
StatePublished - Mar 1 2019

Fingerprint

Rift Valley fever virus
Rift Valley fever
Rift Valley Fever
Antiviral Agents
Mitoxantrone
Azauridine
mice
antiviral agents
screening
National Institutes of Health
Renilla Luciferases
assays
euthanasia
luciferase
nervous system
Euthanasia
disease severity
Ribavirin
signs and symptoms (animals and humans)
placebos

Keywords

  • Antiviral
  • BSL-2 environment
  • Mitoxantrone
  • MP-12 vaccine strain
  • Rift Valley fever virus

ASJC Scopus subject areas

  • Microbiology
  • veterinary(all)

Cite this

Lang, Y., Li, Y., Jasperson, D., Henningson, J., Lee, J., Ma, J., ... Ma, W. (2019). Identification and evaluation of antivirals for Rift Valley fever virus. Veterinary Microbiology, 230, 110-116. https://doi.org/10.1016/j.vetmic.2019.01.027

Identification and evaluation of antivirals for Rift Valley fever virus. / Lang, Yuekun; Li, Yonghai; Jasperson, Dane; Henningson, Jamie; Lee, Jinhwa; Ma, Jingjiao; Li, Yuhao; Duff, Michael; Liu, Haixia; Bai, Dingping; McVey, Scott; Richt, Juergen A.; Ikegami, Tetsuro; Wilson, William C.; Ma, Wenjun.

In: Veterinary Microbiology, Vol. 230, 01.03.2019, p. 110-116.

Research output: Contribution to journalReview article

Lang, Y, Li, Y, Jasperson, D, Henningson, J, Lee, J, Ma, J, Li, Y, Duff, M, Liu, H, Bai, D, McVey, S, Richt, JA, Ikegami, T, Wilson, WC & Ma, W 2019, 'Identification and evaluation of antivirals for Rift Valley fever virus', Veterinary Microbiology, vol. 230, pp. 110-116. https://doi.org/10.1016/j.vetmic.2019.01.027
Lang, Yuekun ; Li, Yonghai ; Jasperson, Dane ; Henningson, Jamie ; Lee, Jinhwa ; Ma, Jingjiao ; Li, Yuhao ; Duff, Michael ; Liu, Haixia ; Bai, Dingping ; McVey, Scott ; Richt, Juergen A. ; Ikegami, Tetsuro ; Wilson, William C. ; Ma, Wenjun. / Identification and evaluation of antivirals for Rift Valley fever virus. In: Veterinary Microbiology. 2019 ; Vol. 230. pp. 110-116.
@article{4c01d66e1d5e4b8f8dab88039c0cbbab,
title = "Identification and evaluation of antivirals for Rift Valley fever virus",
abstract = "Rift Valley fever virus (RVFV) is the causative agent of Rift Valley fever (RVF) that affects both livestock and humans. There are neither fully licensed RVF vaccines available for human or animal use, nor effective antiviral drugs approved for human use in the U.S. To identify antiviral compounds effective for RVF, we developed and employed a cell-based high-throughput assay using a recombinant RVFV MP-12 strain, which expresses Renilla luciferase in place of the NSs protein, to screen 727 small compounds purchased from the National Institutes of Health. Twenty-three compounds were initially identified using the screening assay. Two compounds, 6-azauridine and mitoxantrone, also inhibited the replication of the parental MP-12 strain encoding the NSs gene, with limited cytotoxic effects. The respective 50{\%} inhibitory concentrations were 29.07 μM and 79.85 μM when tested with the parental MP-12 strain at a multiplicity of infection of 2. The compounds were further evaluated using the STAT-1 KO mouse model. At one hour post intranasal inoculation of MP-12 strain, mice were intranasally treated with each indicated compound twice daily. Mice treated with either placebo or 6-azauridine displayed severe weight loss and reached the threshold for euthanasia with obvious neurologic symptoms. Onset of disease was, however, delayed in mice treated with either ribavirin or mitoxantrone. The results indicated that mitoxantrone can reduce the severity of diseases in RVFV-infected mice. Our studies build the foundation for the initial screening and efficacy studies of RVF antivirals in a BSL-2 environment, avoiding the higher risks of BSL-3 exposure with wild-type virus.",
keywords = "Antiviral, BSL-2 environment, Mitoxantrone, MP-12 vaccine strain, Rift Valley fever virus",
author = "Yuekun Lang and Yonghai Li and Dane Jasperson and Jamie Henningson and Jinhwa Lee and Jingjiao Ma and Yuhao Li and Michael Duff and Haixia Liu and Dingping Bai and Scott McVey and Richt, {Juergen A.} and Tetsuro Ikegami and Wilson, {William C.} and Wenjun Ma",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.vetmic.2019.01.027",
language = "English (US)",
volume = "230",
pages = "110--116",
journal = "Veterinary Microbiology",
issn = "0378-1135",
publisher = "Elsevier",

}

TY - JOUR

T1 - Identification and evaluation of antivirals for Rift Valley fever virus

AU - Lang, Yuekun

AU - Li, Yonghai

AU - Jasperson, Dane

AU - Henningson, Jamie

AU - Lee, Jinhwa

AU - Ma, Jingjiao

AU - Li, Yuhao

AU - Duff, Michael

AU - Liu, Haixia

AU - Bai, Dingping

AU - McVey, Scott

AU - Richt, Juergen A.

AU - Ikegami, Tetsuro

AU - Wilson, William C.

AU - Ma, Wenjun

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Rift Valley fever virus (RVFV) is the causative agent of Rift Valley fever (RVF) that affects both livestock and humans. There are neither fully licensed RVF vaccines available for human or animal use, nor effective antiviral drugs approved for human use in the U.S. To identify antiviral compounds effective for RVF, we developed and employed a cell-based high-throughput assay using a recombinant RVFV MP-12 strain, which expresses Renilla luciferase in place of the NSs protein, to screen 727 small compounds purchased from the National Institutes of Health. Twenty-three compounds were initially identified using the screening assay. Two compounds, 6-azauridine and mitoxantrone, also inhibited the replication of the parental MP-12 strain encoding the NSs gene, with limited cytotoxic effects. The respective 50% inhibitory concentrations were 29.07 μM and 79.85 μM when tested with the parental MP-12 strain at a multiplicity of infection of 2. The compounds were further evaluated using the STAT-1 KO mouse model. At one hour post intranasal inoculation of MP-12 strain, mice were intranasally treated with each indicated compound twice daily. Mice treated with either placebo or 6-azauridine displayed severe weight loss and reached the threshold for euthanasia with obvious neurologic symptoms. Onset of disease was, however, delayed in mice treated with either ribavirin or mitoxantrone. The results indicated that mitoxantrone can reduce the severity of diseases in RVFV-infected mice. Our studies build the foundation for the initial screening and efficacy studies of RVF antivirals in a BSL-2 environment, avoiding the higher risks of BSL-3 exposure with wild-type virus.

AB - Rift Valley fever virus (RVFV) is the causative agent of Rift Valley fever (RVF) that affects both livestock and humans. There are neither fully licensed RVF vaccines available for human or animal use, nor effective antiviral drugs approved for human use in the U.S. To identify antiviral compounds effective for RVF, we developed and employed a cell-based high-throughput assay using a recombinant RVFV MP-12 strain, which expresses Renilla luciferase in place of the NSs protein, to screen 727 small compounds purchased from the National Institutes of Health. Twenty-three compounds were initially identified using the screening assay. Two compounds, 6-azauridine and mitoxantrone, also inhibited the replication of the parental MP-12 strain encoding the NSs gene, with limited cytotoxic effects. The respective 50% inhibitory concentrations were 29.07 μM and 79.85 μM when tested with the parental MP-12 strain at a multiplicity of infection of 2. The compounds were further evaluated using the STAT-1 KO mouse model. At one hour post intranasal inoculation of MP-12 strain, mice were intranasally treated with each indicated compound twice daily. Mice treated with either placebo or 6-azauridine displayed severe weight loss and reached the threshold for euthanasia with obvious neurologic symptoms. Onset of disease was, however, delayed in mice treated with either ribavirin or mitoxantrone. The results indicated that mitoxantrone can reduce the severity of diseases in RVFV-infected mice. Our studies build the foundation for the initial screening and efficacy studies of RVF antivirals in a BSL-2 environment, avoiding the higher risks of BSL-3 exposure with wild-type virus.

KW - Antiviral

KW - BSL-2 environment

KW - Mitoxantrone

KW - MP-12 vaccine strain

KW - Rift Valley fever virus

UR - http://www.scopus.com/inward/record.url?scp=85061154262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061154262&partnerID=8YFLogxK

U2 - 10.1016/j.vetmic.2019.01.027

DO - 10.1016/j.vetmic.2019.01.027

M3 - Review article

VL - 230

SP - 110

EP - 116

JO - Veterinary Microbiology

JF - Veterinary Microbiology

SN - 0378-1135

ER -